Autologous cord blood stem cells for autism
Overview:
The purpose of this trial is to determine the effect of umbilical
cord blood infusion in treating children with autism. The trial is
being undertaken by the Sutter Institute for Medical Research in
Sacramento California and expects to recruit 30 children from 2 to 7
years of age that have been diagnosed with autism. Participants will
be randomly divided into two groups. One group will receive an
infusion of their own umbilical cord blood (initial experimental
group). The other group will receive a placebo infusion of saline,
but then after 24 weeks, they will receive their own umbilical cord
blood. The initial experimental group will receive a placebo
injection at 24 weeks. Both groups will be tested at 24 weeks after
initial infusion, and then again after another 24 weeks. The
participants, their carers and their doctors will not know which
group they have been assigned to. In the follow-up period each child
will be monitored for complications and changes in their clinical
condition.
Location: California, USA
Trial design: Efficacy study
Status: Open – recruiting
Find out more
Autologous umbilical cord blood infusion for children with autism spectrum disorder
Overview:
This study is being undertaken at the Duke University Medical
Centre. The study is a prospective phase 1 single-centre trial
designed to determine the safety of a single intravenous infusion of
autologous umbilical cord blood in children with Autism Spectrum
Disorder (ASD). The trial aims to recruit 20 children between 24 and
72 months of age with a diagnosis of ASD with stored autologous
(their own) cord blood. Participants in the study will receive an
infusion of their own cord blood, with follow up assessments at 6
and 12 months after the infusion.
Location: North Carolina, USA
Trial design: Safety and efficacy
Status: Active – not yet recruiting
Find out more